The Myasthenia Gravis (MG) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The Myasthenia Gravis (MG) is a chronic, progressive, and rare neuromuscular disorder that is characterized by weakness of the head, limb, spinal, eye, and respiratory muscles. In MG, antibodies are produced against the acetylcholine receptor (AchR) that impedes the normal transmission of electrical signals from nerves to muscles. MG is often called the “snowflake disease” affecting about 15 in every 100,000 people in the UK.
Myasthenia Gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and women during their 20s or 30s. There is no proven cure for myasthenia gravis, however, patients can be treated with medications and surgery for the management of the symptoms. The overall EU myasthenia gravis market was valued at USD 0.67 billion in 2019.
Market Growth Drivers
The rise in incidence rate is one of the major factors driving the demand for myasthenia gravis treatment. Advances in technology, rising acceptance of immunotherapies, approval of promising medications, the emergence of biologics are all driving market expansion.
Awareness programs and initiatives are taken by non-profit organizations in UK such as Duchenne UK, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD) and government support in product research & development is expected to create market opportunities during the forecast period.
On the downside, the high cost of MG treatment and ignorance of signs and symptoms are likely to continues to hinder market proliferation to a certain extent.